Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and private sector and Cobra Biologics' ambitious plans for 2022.
Can you please introduce Cobra Biologics to our international readers?
"The philosophy behind the Cobra development is to work closely with our customers and expand through their future commitment to support shareholder investment and government grants."
